Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

Theralase Technologies Inc. has announced significant preclinical findings showing that its lead drug formulation, Ruvidar(TM), is more effective than Acyclovir in targeting the Herpes Simplex Virus 1 (HSV-1). This finding positions Ruvidar(TM) as a potent alternative to traditional antiviral treatments.

The studies conducted at the University of Manitoba demonstrate that Ruvidar(TM) not only outperforms Acyclovir in inhibiting virus replication but is also effective when administered after infection. This improves upon Acyclovir, which fails to prevent HSV-1 replication if added one day post-infection. Notably, Ruvidar(TM) reduced HSV-1 replication by 10 million-fold under these conditions.

Theralase’s CEO, Roger DuMoulin-White, states that the company is now seeking partnerships or licensing opportunities to advance Ruvidar(TM) for both topical and oral treatments targeting herpes simplex.

These findings underscore Ruvidar(TM)'s potential in the antiviral drugs market, projected to reach USD 71.1 billion by 2032, and offer new avenues for prophylactic and treatment applications.